Free shipping on all orders over $ 500

Lifirafenib (BGB-283)

Cat. No. M10475
Lifirafenib (BGB-283) Structure
Synonym:

Beigene-283

Size Price Availability
10mg USD 230  USD230 4-7 Days
25mg USD 500  USD500 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant. In BRAFV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. BGB-283 inhibits the EGF-induced EGFR autophosphorylation on Tyr1068 in A431 cells in a dose-dependent manner.

In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell-line derived and primary human colorectal tumor xenografts bearing B-RAFV600E mutation.

Chemical Information
Molecular Weight 478.42
Formula C25H17F3N4O3
CAS Number 1446090-79-4
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Xi Yuan, et al. Mol Oncol. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors

[2] Xueting Yao, et al. J Pharm Biomed Anal. A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study

[3] Hiroshi Kotani, et al. Oncogene. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers

[4] Zhiyu Tang, et al. Mol Cancer Ther. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

Related Raf Products
Cyclorasin 9A5

Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the Ras-Raf protein interaction with an IC50 of 120 nM.

R18

R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM.

PROTAC RAF degrader 1

PROTAC RAF degrader 1 is a PROTAC RAF degrader.

B-Raf IN 15

B-Raf IN 15 is a BRAF inhibitor.

Raf inhibitor 3

Raf inhibitor 3 is a Raf inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Lifirafenib (BGB-283), Beigene-283 supplier, Raf, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.